The distribution and sophistication of High Throughput Screening (HTS) infrastructure across Mainland China are not uniform, reflecting strategic regional concentrations of pharmaceutical and academic R&D activity. Major economic and scientific hubs such as Shanghai, Beijing, and the Guangdong-Hong Kong-Macao Greater Bay Area have emerged as the primary centers for HTS investment...